Objective: The objective of this study was to determine what impact the omission of respiratory events scored during wake epochs has on the generation of the apnea/hypopnea index (AHI) using computerised polysomnography (PSG).
Materials And Methods: Sixty diagnostic PSG recordings were scored using the recommended method of sleep staging with epochs. In addition, absolute sleep scoring criteria was used to calculate the total sleep time (TST). The TST, respiratory events and AHI generated from both scoring methods were compared.
Results: The AHI from epoch scoring (AHI(EP)) was significantly less than that derived from absolute sleep staging (AHI(ABS)) [AHI(EP) = 15.8 events/hour (7.3, 38.2), AHI(ABS) = 18.8 events/hour (8.7, 40.2); p < 0.0001]. From a total of 8,820 legitimately scored respiratory events ≥10 s duration, 723 (8%) were excluded from the AHI(EP) calculation as they were identified as having occurred during wake, but 400 of these (57%) started in an epoch of wake and continued into epoch(s) of sleep. These omitted events were not trivial [median 16.6 s (13.0, 24.0)] and were frequently associated with oxygen desaturation events [median 4% (3.0, 7.0)] with a range of 3% to 39%.
Conclusion: The use of arbitrarily defined epochs for sleep staging has a direct impact on legitimately scored respiratory events resulting in the systematically incorrect reporting of the AHI. This artefact is due to computerised data reduction excluding all respiratory events that are contained within an epoch(s) of wake as well as those that start in an epoch scored as wake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11325-010-0344-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.
Cancer Med
February 2025
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.
Methods: Between 12/2019 and 06/2022, 237 patients were included.
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
Clin Lung Cancer
January 2025
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Although chemoimmunotherapy is recommended for advanced nonsquamous non-small cell lung cancer (NSCLC) with low programmed cell death ligand 1 (PD-L1) expression, no head-to-head comparisons of immune checkpoint inhibitors (ICIs) have been performed. Therefore, we compared the effect and safety of regimens in these patients to guide evidence-based treatment.
Methods: This retrospective study included patients with advanced nonsquamous NSCLC with a PD-L1 tumor proportion score of 1% to 49% administered ICI combination platinum-based chemotherapy between May 2018 and May 2023 at 19 institutions in Japan.
Introduction: Elexacaftor/tezacaftor/ivacaftor (ETI) has shown significant improvements in pulmonary and nutritional status in persons with cystic fibrosis (pwCF). Less is known about the extrapulmonary impact of ETI and effects on airway microbiology, lung clearance index (LCI) and fraction of exhaled nitric oxide (FeNO).
Methods: A multicentre prospective observational trial, including 79 pwCF ≥ 18 years eligible for ETI.
Decoding the SARS-CoV-2 infection process: Insights into origin, spread, and therapeutic approaches.
Microb Pathog
January 2025
Department of Bioengineering, Faculty of Engineering, Integral University, Lucknow, 226026, India. Electronic address:
Globally, over 768 million confirmed cases and 6.9 million deaths had been documented as of July 17, 2023. Coronaviruses have a relatively large RNA genome.
View Article and Find Full Text PDFIntranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
Lancet Neurol
February 2025
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada; Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada. Electronic address:
Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings on the Neuropsychiatric Inventory over 1 week and, in a randomised, double-blind, placebo-controlled, crossover study, a single dose of 72 IU oxytocin increased blood-oxygen-level-dependent signal in limbic brain regions. We aimed to determine whether longer treatment with oxytocin improves apathy in people with frontotemporal dementia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!